Previous studies have reported that dasatinib reduced tumor growth and increased CD8 T cell infiltration in various cancers, including B16.OVA melanoma, 1956 sarcoma, MC38 colon, and 4T1 breast carcinoma [74]. This evidence concerns the gene CD8A and sarcoma.